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INTRODUCTION
Preeclampsia and eclampsia are pregnancy compli-
cations that could cause maternal and perinatal
death. Global burden of diseases 2000 estimated
that the incidence of preeclampsia was around
2.8% of live births in developing countries and
0.4% in developed countries. Incidence of eclamp-
sia was around 2.3% of preeclampsia in developing
countries and 0.8% in developed countries.1
According to Godlin (1982), HELLP syndrome
was an initial form of severe preeclampsia while
Weinstein (1982) reported HELLP syndrome as a
unique variety of preeclampsia.2 HELLP syndrome
incidence was around 2 - 20% of severe pree-
clampsia and around 0.2-0.6% of pregnancies.2,3
Etiology and pathogenesis of HELLP syndrome are
always associated to preeclampsia, although etiol-
ogy and pathogenesis of preeclampsia itself are not
fully understood to these days.
Abstract
Objectives: To understand the expression of placental vascular en-
dothelial growth factor receptor (VEGFR-1) in severe preeclampsia
with complication (eclampsia and HELLP syndrome).
Methods: The study was an observational study with cross sectional
design, performed at several hospitals of Department of Obstetrics
and Gynecology Medical Faculty of University of Hasanuddin,
Makassar. Subjects met to inclusion criteria were taken as samples.
Placental tissue samples were taken from cord insertion site and fix-
ated with formalin buffer solution. Immunohistochemical examina-
tion was performed at Center of Research University of Hasanuddin.
Antibody used were primary antibody of Mouse monoclonal anti
VEGFR-1 antibody (Santa Cruz) dissolved to 1:100 and link antibody
(secondary antibody labeled with biotin) (Dakopatt). Placental tis-
sues were examined in Streptavidin biotin peroxides and inter-
preted according to the intensity of trophoblast cytoplasmic dye.
Results: High VEGFR-1 expression was found in 100% of the pla-
centa from patients with eclampsia , 42.9&% in patients with HELLP
syndrome and 37.8% in patients with severe preeclampsia. High
VEGFR-1 expression was correlated to incidence of eclampsia
(p=.000) and not correlated to severe preeclampsia and HELLP syn-
drome (p=0.734).
Conclusion: High VEGFR-1 expression was correlated to eclampsia
and not correlate to severe preeclampsia and HELLP syndrome.
[Indones J Obstet Gynecol 2012; 36-3:116-20]
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Abstrak
Tujuan: Untuk mengetahui ekspresi vascular endothelial growth
factor receptor-1 (VEGFR-1) plasenta pada penderita preeklampsia
berat, eklampsia dan sindroma HELLP.
Metode: Penelitian ini adalah penelitian observasional dengan desain
studi potong lintang yang dilaksanakan pada beberapa rumah sakit
pendidikan di Bagian Obstetri dan Ginekologi Fakultas Kedokteran
Universitas Hasanuddin, Makassar. Sampel dari subjek yang me-
menuhi kriteria inklusi diambil dari plasenta pada tempat daerah in-
sersi tali pusat, kemudian difiksasi dengan larutan formalin buffer. Pe-
meriksaan imunohistokimia plasenta dilakukan di Pusat Kegiatan
Penelitian UNHAS. Antibodi yang digunakan adalah antibodi primer
Mouse monoclonal anti VEGFR-1 antibody (Santa Cruz) yang dilarut-
kan 1:100 dan link antibody (antibodi sekunder yang dilabel dengan
biotin) (Dakopatt). Sediaan plasenta diperiksa dengan Streptavidin
biotin peroksidase, kemudian interpretasinya dinilai berdasarkan in-
tensitas pewarnaan sitoplasma sel trofoblas.
Hasil: Pada plasenta penderita eklampsia ditemukan 100% ekspresi
kuat VEGFR-1 dibandingkan pada sindroma HELLP (42.9%) dan
preeklampsia berat (37.8%). Ekspresi kuat VEGFR-1 berhubungan
dengan kejadian eklampsia (p=.000) dan tidak berhubungan dengan
preeklampsia berat dan sindroma HELLP (p=.734).
Kesimpulan: Ekspresi kuat VEGFR-1 pada plasenta berhubungan
dengan eklampsia dan tidak berhubungan dengan kejadian pre-
eklampsia berat dan sindroma HELLP.
[Maj Obstet Ginekol Indones 2012; 36-3:116-20]
Kata kunci: eklampsia, ekspresi VEGFR-1, preeklampsia berat, sin-
droma HELLP.
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Preeclampsia is considered as an antiangiogenic
condition.4 Recent studies showed that ischemic
trophoblast synthesized antiangiogenic factors.5
Hypoxia stimulated some protein expression in-
cluding endothelin, vascular endothelial growth
factor (VEGF) and vascular endothelial growth fac-
tor receptor-1 (VEGFR-1). VEGF is a potent mito-
genic and angiogenic factor for endothelial cells.
VEGF and placental growth factor (PlGF) bound to
abundant VEGFR-1 may take place in pathogenesis
of maternal symptoms in preeclampsia.6 Specifi-
cally, Maynard et al (2003) proposed a hypothesis
stated that in pregnant women with preeclampsia,
there was an increase of sVEGFR-1 produced by
placenta in the circulation, which then bound the
free VEGF and PlGF. As a consequence, normal vas-
cularization in the kidney, lungs, and other vital or-
gans fell to/became dysfunction. Also, injection of
sVEGFR-1 into animal induced hypertension, pro-
teinuria and glomerular endotheliosis, symptoms
classic to preeclampsia.7 Hence, VEGFR-1 may be
the missing link between implantation disorder
and preeclampsia maternal symptoms.8 This study
would like to show the VEGFR-1 expression in the
placenta.
The remaining question is whether VEGFR-1
plays an important role in pathogenesis of HELLP
syndrome and eclampsia. To these days, there is
no study compares the expression of placental
VEGFR-1 between severe preeclampsia and eclam-
psia or HELLP syndrome.
The aim of the study was to understand the ex-
pression of placental vascular endothelial growth
factor receptor (VEGFR-1) in severe preeclampsia
with complication (eclampsia and HELLP syn-
drome).
METHODS
This study was performed from November 2010 to
January 2011 at several hospitals of Department of
Obstetrics and Gynecology Faculty of Medicine
University of Hasanuddin, Makassar.
Subjects were pregnant women with severe
preeclampsia who met the inclusion criteria and
taken by sonsecutive sampling.
Placental tissue samples were taken from cord
insertion site and fixated with formalin buffer so-
lution. Immunohistochemical examination was
performed at Center of Research University of
Hasanuddin. Antibody used were primary antibody
of Mouse monoclonal anti VEGFR-1 antibody
(Santa Cruz) dissolved to 1:100 and link antibody
(secondary antibody labeled with biotin) (Dak-
opatt). Placental tissues were examined in Strepta-
vidin biotin peroxides and interpreted according to
intensity of trophoblast cytoplasmic dye.
Score 0 (negative) means that no dyed cell was
found. Score +1 (low) means that <10% dyed tro-
phoblast with weak/moderate intensity was found.
Score +2 (low) means that 10-50% dyed tro-
phoblast with weak/moderate intensity, or >50%
with weak intensity was found. And score +3 (high)
means that >50% dyed trophoblast with moder-
ate/strong intensity was found.
The data analysis was performed using Kruskal
Wallis test, Mann Whitney test and Chi-square test
to compare between two unpaired variable groups.
RESULTS
The total of samples obtained were 61 samples,
devided into 37 samples of severe preeclampsia, 14
samples of HELLP syndrome, and 10 samples of
eclampsia.
 
Figure 1a. Immunohistochemical dyeing of placental
VEGFR-1 expression (score 0).
 
Figure 1b. Immunohistochemical dyeing of placental
VEGFR-1 expression (score +1).
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There was no significant difference in the sub-
ject characteristics of maternal age, parity, systolic
blood pressure, diastolic blood pressure, and pro-
teinuria.
Table 1. Characteristic distribution of samples
Variable
Group*
p
Severe Pre-
eclampsia Eclampsia
HELLP
syndrome
Age 28.3±7.3 24.2±6.4 28.6±6.7 0.215
Parity  1.8±0.9  1.3±0.5  1.7±0.9 0.309
Systolic BP 168.9±20.5   176±23.2 171.4±12.3 0.475
Diastolic BP 108.1±13.1   116±11.7 112.1± 8.9 0.113
Proteinuria  3.0±0.7  3.4±0.5  3.2±0.4 0.197
* Mean
Using Kruskal Wallis test, we found significant
difference (p<0.05) of VEGFR-1 expression be-
tween severe preeclampsia, HELLP syndrome and
eclampsia group. Percentage of score +3 in eclamp-
sia group (100%) was higher than others.
Since there was significant difference found
among the three groups, we performed further
analysis test between two groups by Mann Whit-
ney test. Significant difference were found between
severe preeclampsia and eclampsia groups
(p=0.007) and between eclampsia and HELLP syn-
drome groups (p=0.014). There was no significant
difference between severe preeclampsia and HELLP
syndrome groups (p=0.745).
Table 2. Expression of placental VEGFR-1 in severe pre-
eclampsia, eclampsia and HELLP syndrome
VEGFR-1
expression
Severe
preeclampsia
Eclampsia HELLP
syndrome
Total
n % n % n % n %
Score  3   8.1  0   0  0   0   3   4.9
Score +1 12  32.4  0   0  5  35.7 17  27.9
Score +2  8  21.6  0   0  3  21.4 11  18  
Score +3 14  37.8 10 100  6  42.9 30  49.2
 Total 37 100  10 100 14 100  61 100  
Chi Square Test, p=0.032
Group severe preeclampsia and eclampsia, p=0.007
Group severe preeclampsia and HELLP syndrome, p=0.745
Group eclampsia and HELLP syndrome, p=0.014
We looked for correlation between high VEGFR-
1 expression (score +3) and complication (com-
bined groups of eclampsia and HELLP syndrome).
The percentage of sample with score +3 was higher
in severe preeclampsia with complication (66.7%)
than without complication (37.8%). There was sig-
nificant difference (p=0.028) in the strength of
VEGFR-1 expression between the group with com-
plication of severe preeclampsia (3.3 times risk)
and the group with no complication.
Table 3. Strength of VEGFR-1 Expression Based on
Complication of Severe Preeclampsia
VEGFR-1
expression
Severe
preeclampsia
Eclampsia+
HELLP syndrome
Total
n % n % n %
High expression 14  37.8 16  66.7 30  49.2
Low expression 23  62.2  8  33.3 31  50.8
 Total 37 100  24 100  61 100  
Chi-Square test, p=0.028, OR 3.286 (95% CI 1.118-9.654)
We also looked for correlation between high
VEFGR-1 expression (score +3) and eclampsia. The
percentage of samples with score +3 was higher in
patients with eclampsia (100%) than in combined
 
Figure 1d. Immunohistochemical dyeing of placental
VEGFR-1 expression (score +3).
 
Figure 1c. Immunohistochemical dyeing of placental
VEGFR-1 expression (score +2).
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groups of HELLP syndrome and severe preeclamp-
sia (39.2%). There was significant correlation
(p=0.000) in the strength of VEGFR-1 correlation
between eclampsia and combined groups of HELLP
syndrome and severe preeclampsia. We could not
estimate the risk since there was no low expression
in eclampsia. However, it is a very significant ex-
pression because all eclampsia samples showed
high expression of VEGFR-1.
Table 4. Strength of VEGFR-1 Expression on Eclampsia
Compared to HELLP Syndrome  and Severe Preeclampsia
VEGFR-1
expression
Severe preeclampsia
HELLP syndrome
Eclampsia Total
n % n % n %
High expression 20  39.2 10 100 30  49.2
Low expression 31  60.8  0   0 31  50.8
 Total 51 100  10 100 61 100  
Chi-Square test, p=0.000, OR 0.667 (95% CI 0.518-0.859)
DISCUSSION
We found that the expression of VEGFR-1 in the
placenta of severe preeclampsia, eclampsia and
HELLP syndrome, varied from score 0 (4.9%),
score +1 (27.9%), score +2 (18%) to score +3
(49.2%). It was in accordance with previous stud-
ies, which stated that in preeclamptic condition, ex-
pression of VEGFR-1 in syncitiotrophoblast was
very high and the soluble level in maternal serum
was also increased.8,9 Helske et al found expression
of VEGFR-1 in 50% syncitiotrophoblast of severe
preeclampsia. The only 50% expression was ex-
plained by individual variation among the patients
based on gestational age and severity of pree-
clampsia.8 In this study, we found that VEGFR-1 ex-
pression in 95.1% of total samples or 91.9% of se-
vere preeclampsia samples. This difference might
be caused by homogenity in our sample charac-
teristics and inclusion criteria of term pregnancy.
We found significant difference in VEGFR-1 ex-
pression among severe preeclampsia, eclampsia
and HELLP syndrome. The higher the VEGFR-1 ex-
pression in the placenta, the more severe the com-
plication of preeclampsia. This was seen as 100%
of the samples with eclampsia had VEGFR-1 ex-
pression score +3, while only 37.8% of samples
with severe eclampsia had VEGFR-1 expression
score +3. The more severe the hypoxia, the higher
the VEGFR-1 synthesis that will worsen the severe
preeclampsia.10 In eclampsia, there are cerebral
edema and neurological complications that do not
relate to the grade of hypertension (found also in
normotension) and are reversible. It showed that
edema might relate to the diminished autoregula-
tion of cerebral blood flow, caused by endothelial
dysfunction, and not because of the autoregulatory
breakdown of cerebral blood flow. Findings in the
head CT scan and MRI of eclampsia were similar
with that of posterior reversible encephalopathy
syndrome (PRES), with vasogenic cerebral edema
and infarct. Findings with these characteristics
were correlated with acute encephalopathy hyper-
tension in conjunction with renal disease and im-
munosuppressive condition, for examples like in
treatment of antiangiogenic agent for cancer ther-
apy. This correlation supported the involvement
of antiangiogenic factors in pathophysiology of
eclampsia.11,12 Blood pressure characteristics, both
systole and diastole, in severe preeclampsia and
eclampsia were homogen and thus supported the
statement above.
VEGFR-1 expression was not significantly differ-
ent between severe preeclampsia and HELLP syn-
drome. We performed further analysis to HELLP
syndrome group. First test was performed to cor-
relate the high VEGFR-1 expression to severe pree-
clampsia group (37.8%) versus combined groups
of HELLP syndrome and eclampsia (66.7%). Sec-
ond test was performed to correlate the high
VEGFR-1 expression to combined groups of severe
preeclampsia and HELLP syndrome (39.2%) ver-
sus eclampsia group (100%). The results showed
that HELLP syndrome might not be a complication
with similar pathogenesis with eclampsia. This can
be interpreted as whether HELLP syndrome is a
variant of severe preeclampsia or HELLP syndrome
has causative factors other than VEGFR-1.13,14
HELLP syndrome may have a pathogenesis that
different from severe preeclampsia. Some studies
found endoglin (Eng) expression, an anti-angio-
genicprotein, in abundance in preeclamptic pla-
centa. Extracellular domain of Eng can be detached
and found in serum as soluble endoglin (sEng).
sEng regulates vascular tonus by interaction with
endothelial nitric oxide synthase. sEng will induce
a milder form of proteinuria and hypertension than
VEGFR-1. sEng and VEGFR-1 induce endothelial
dysfunction through different mechanism. But
when sEng were expressed concurrently with
VEGFR-1, the developed preeclampsia will be ac-
companied with thrombocytopenia and elevated
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liver enzyme as seen in HELLP syndrome.3,15 sEng
is also elevated in maternal serum several months
before the onset of preeclampsia, thus sEng can be
used as a predictor for patients who may undergo
a severe variant of preeclampsia.15
From this study, it was concluded that the high
expression of placental VEGFR-1 was correlated
with eclampsia and there was no difference in pla-
cental VEGFR-1 expression between severe pree-
clampsia and HELLP syndrome.
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